Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolarity type I, Manic or Mixed Episode With or Without Psychotic Features.
Understand this study
Who could participate?
Listed age limits: 10 years to 17 years.
What will I do during this study?
The study group receives aripiprazole as a study medication.
- Listed locations
- Dothan and 100 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 524
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Croatia, ...
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT01122927
- Official title
Show the full official title
A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia or Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Recruitment & locations
Dothan, United States · Downey, United States · Miami, United States
87 more locations
- Atlanta, United States
- Smyrna, United States
- Oak Brook, United States
- Wichita, United States
- Minneapolis, United States
- Buffalo, United States
- Stony Brook, United States
- Chapel Hill, United States
- Cincinnati, United States
- Cleveland, United States
- Oklahoma City, United States
- Philadelphia, United States
- Houston, United States
- San Antonio, United States
- The Woodlands, United States
- Richmond, United States
- Bellevue, United States
- Bothell, United States
- Milwaukee, United States
- Burgas, Bulgaria
- Pazardzhik, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Varna, Bulgaria
- Rijeka, Croatia
- Zagreb, Croatia
- Budapest, Hungary
- Gyula, Hungary
- Szeged, Hungary
- Vijayawada, India
- Visakhapatnam, India
- Ahmedabad, India
- Maninagar, Ahmedabad, India
- Mangalore, India
- Calicut, India
- Nashik, India
- Ludhiana, India
- Jaipur, India
- Chennai, India
- Maduri, India
- Kanpur, India
- Lucknow, India
- Varanasi, India
- Guntur, India
- Kuala Lumpur, Malaysia
- Dasmariñas, Philippines
- Manila, Philippines
- Iloilo City, Philippines
- Mandaluyong, Philippines
- Bialystok, Poland
- Gdansk Wrzeszcz, Poland
- Torun, Poland
- Wroclaw, Poland
- Cluj-Napoca, Romania
- Timișoara, Romania
- Bucharest, Romania
- Craiova, Dolj, Romania
- Iași, Romania
- Nizhny Novgorod, Russia
- Novosibirsk, Russia
- Tonnelnyi Township, Russia
- Kazan', Russia
- Lipetsk, Russia
- Moscow, Russia
- Orenburg Region, Russia
- Petrozavodsk, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Tomsk, Russia
- Yaroslavl, Russia
- Yekaterinburg, Russia
- Belgrade, Serbia
- Novi Sad, Serbia
- Taipei, Taiwan
- Dnipro, Ukraine
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Luhansk, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Simferopol Crimea, Ukraine
- Temopil, Ukraine
- Vinnytsia, Ukraine
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including Aripiprazole.
Who can participate?
Listed age limits: 10 years to 17 years.
Is this study still recruiting?
The registry lists this study as terminated.
